Biologics for Orth/Musculoskeletal: 50.0% of denials overturned
In 20 California IMR decisions from 2018 to 2025, reviewers overturned 10 (50.0%). In the last five years: 62.5% of 8. 15 were medical-necessity disputes, 5 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2022 | 1 | 0.0% |
| 2023 | 3 | 66.7% |
| 2024 | 3 | 66.7% |
| 2025 | 1 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 8 | 50.0% | 50.0% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 8 | 62.5% | 50.0% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 5 | 20.0% | 50.0% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 5 | 60.0% | 50.0% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 3 | 0.0% | 50.0% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 3 | 0.0% | 50.0% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Evenity. Evenity (romosozumab) is an anabolic agent approved by the U.S. Food and Drug Administration (FDA) based on trials showing a reduction in vertebral and nonvertebral fractures with romosozumab compared with placebo or with alendronate. Additionally, a trial showed that patients with …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The parent of a patient has requested authorization and coverage for Humira SQ injection pen kit. The current medical literature establishes that consensus treatment plans for chronic recurrent multifocal osteomyelitis (CRMO) include non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate, and anti-tumor necrosis factor (TNF) therapy, such as Humira. One clinical study concluded …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for Krystexxa injections of 8 mg every two weeks for 9-12 months. The American College of Rheumatology (ACR) guidelines recommend treatment with Krystexxa over the continuation of uric acid lowering therapy for patients with two or more gout flares per year who are not …”
And one the reviewer upheld
“The physician reviewer found that the patient requested reimbursement for the graft product, Neox Cord/Clarix Cord. The amniotic membrane-umbilical cord (AM-UC) allograft, like the Neox Cord/Clarix Cord at issue, is a regenerative orthobiologic adjunct that modulates wound healing by down-regulating inflammation, enhancing local healing and antimicrobial factors, as well as reducing scar formation. The authors of a study indicated that …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Biologics denials for Orth/Musculoskeletal overturned?
In 20 California IMR decisions from 2018 to 2025, reviewers overturned 10 (50.0%). In the last five years: 62.5% of 8. 15 were medical-necessity disputes, 5 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.